Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FIN 211

Drug Profile

FIN 211

Alternative Names: FIN-211

Latest Information Update: 17 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Finch Therapeutics Group
  • Class Bacteria; Behavioural disorder therapies
  • Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Pervasive child development disorders

Most Recent Events

  • 01 Sep 2022 Finch Therapeutics suspended the initiation of phase Ib AUSPIRE trial in pervasive child development disorders (autism spectrum disorder) and gastrointestinal symptoms in the US
  • 16 May 2022 Finch Therapeutics announces intention to submit an IND application for Pervasive child development disorders in the fourth quarter of 2022
  • 31 Mar 2022 Finch Therapeutics plans the phase Ib AUSPIRE trial for Pervasive child development disorders and Gastrointestinal symptoms (In children) in third quarter of 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top